<DOC>
	<DOCNO>NCT00005942</DOCNO>
	<brief_summary>Phase I/II trial study effectiveness liposomal daunorubicin SU5416 treat patient hematologic cancer respond initial therapy . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . SU5416 may stop growth hematologic cancer stop blood flow cancer</brief_summary>
	<brief_title>Liposomal Daunorubicin SU5416 Treating Patients With Hematologic Cancer That Has Not Responded Initial Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose SU5416 administer daunorubicin liposomal patient acute myeloid leukemia , refractory anemia excess blast ( RAEB ) , RAEB transformation , chronic myelomonocytic leukemia complete remission 21-50 day one course induction chemotherapy . II . Determine efficacy regimen patient . III . Determine qualitative quantitative toxicity regimen patient . OUTLINE : This dose escalation study SU5416 . Patients receive daunorubicin liposomal IV 6 hour day 1-3 SU5416 IV twice week 2 month . The second course administer 1 month , treatment continue every 4-6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos SU5416 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Adult patient AML , RAEB , RAEBT CMMLT CR 2150 day begin course one initial induction chemotherapy ; patient may receive 1 prior course chemotherapy prior study entry ; must contain AraC dose least 1 g/m^2 daily x 4 day either topotecan anthracycline standard dos ( i.e. , daunorubicin = &lt; 65 mg/m^2 daily x 3 day , idarubicin 12 mg/m^2 daily x 3 day ) ; patient begin liposomal Daunorubicin day 21 42 course one must persistent blast bone marrow blood without evidence improvement ; patient begin liposomal Daunorubicin day 42 50 may may persistent blast must thrombocytopenia neutropenia improve Patients must recover toxic effect prior therapy minimum interval 14 day prior therapy must receive recombinant growth factor period Patients racial ethnic group Zubrod performance status = &lt; 1 Total bilirubin value = &lt; 1.5 mg/dL Serum creatinine value = &lt; 1.5 mg/dL Serum sGOT sGPT = &lt; 2.5 time upper lim normal Patients must agree practice approve method birth control ( applicable ) Patients must provide write informed consent Patients gender ethnic background may include ; last 5 year , 356 patient relapsed refractory acute leukemia would meet eligibility criterion study treat M.D . Anderson Cancer Center , annual average 70 patient ; race ( defined patient admission questionnaire ) sex distribution patient Concurrent cancer chemotherapy , systemic radiotherapy surgery Patients evidence active infectious process receive antibiotic therapy infectious process , either document presumed , time study entry 2 week prior study entry Because potential effect SU5416 embryo , woman potential become pregnant , unless utilizing birth control , pregnant exclude study ; negative pregnancy test must document screening period woman childbearing potential ; breastfeed woman exclude trial potential toxicity child ; men childfathering potential use medically acceptable form birth control study Overt psychosis mental disability otherwise incompetent give inform consent Receipt follow prior SU5416 administration : major surgery within 2 week ; minor surgery within 1 week previous angiogenesis inhibitor therapy ( include metalloproteinase inhibitor , thalidomide , antiVEGF/Flk1 monoclonal antibody therapy investigational drug act directly VEGF/Flk1 signal pathway ) organ transplant time Known allergy Cremophor beta Cremophor betabased drug product , corticosteroid ; H1 blocker , H2 blocker paclitaxel ; patient uncompensated coronary artery disease electrocardiogram physical examination , history myocardial infarction severe/unstable angina past 6 month eligible ; patient cardiac leave ventricular ejection fraction ( LVEF ) MUGA echocardiography &lt; 40 % eligible Patients diabetes mellitus others severe peripheral vascular disease patient deep venous arterial thrombosis ( include pulmonary embolism ) within 3 month entry eligible Prior CNS hemorrhage prior sterotactic CNS radiation Any acute chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation/study drug administration may interfere interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>